Johannesburg. Aspen (APN), South Africa’s leading pharmaceutical company, has announced that Irish-based Tibotec Pharmaceuticals has granted it a non-exclusive license to manufacture, market and distribute the Anti-retroviral (“ARV”) compound, rilpivirine hydrochloride (TMC278), pending approval of the molecule which could then be prescribed for patients commencing ARV treatment for the first time as well as for… Continue reading Aspen granted generic license for the manufacture and supply of TMC278
Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform to be released on 4 March 2024.
